Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

By Ahmed Aboulenein and Maggie Fick WASHINGTON (Reuters) -AstraZeneca plans to spend $50 billion to expand manufacturing and ...

Shares of AstraZeneca were trading at $72.66 as of July 25. Over the last 52-week period, shares are down 7.46%. Given that these returns are generally negative, long-term shareholders are likely ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

"attachment_1199068" align="aligncenter" width="1456"] A pharmacy worker distributing prescription medicines to ...

The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.